Ethical division: the brand stays here, the demand is built with prescribers
A different arrangement from the franchise, not a better one. It is the right one when the brand is meant to outlive any single territory.
- Injectables in range
- 300
- Therapeutic groups
- 11
- Supplying
- 15 yrs
What ethical means in this trade, and what it does not
In the Indian pharmaceutical market, ethical describes how a product reaches the patient, not how virtuous the company is. An ethical product is promoted to the prescriber, dispensed against a prescription and moved through the stockist and distributor chain. The brand belongs to the manufacturer throughout. Nobody is appointed to own a territory.
That is a genuinely different arrangement from the franchise, where the partner holds the district and the invoice. Here the field effort is aimed at the clinician who writes the product, and stock flows to wherever those prescriptions are being dispensed. Demand follows the prescriber rather than the territory boundary.
The second meaning of the word does apply, and it now has statutory weight behind it. The Uniform Code for Pharmaceutical Marketing Practices issued by the Department of Pharmaceuticals in March 2024 directs compliance rather than inviting it, as the 2014 code did. Everything below is written to that code.
Suited to
- Building one brand across several states
- Molecules where the prescriber decides, not the counter
- Companies with a field force already calling on clinicians
- Long horizon brands rather than a fast territory return
Ethical division or PCD franchise
The two are often presented as the same offer with different words. They are not, and the difference decides which one is right for you.
Four rules the field effort runs on
Written down because a promotional claim that cannot be traced to the approved information is a regulatory exposure for the manufacturer, not a clever line.
Claims trace to the approved information
Anything said about a product in a detail or on a visual aid comes from the approved prescribing information for that product. If it is not in there, it is not said.
Benefit and risk both stated
Contraindications, cautions and known adverse effects are part of the detail, not an omission left for the package insert to handle. Clinicians notice which companies do this.
No inducement, in any form
The 2024 code is explicit on gifts, hospitality and travel. Our field effort is a visual aid, a sample where it is lawful, and the time of someone who understands the molecule.
Records kept
Promotional material, samples issued and the claims made are recorded, which is the only way a company can demonstrate compliance rather than assert it.
From molecule to a repeat prescription
Segment and molecule selected
Which therapeutic group, which prescriber, which institution type. A critical care injectable is decided in an ICU, not at a retail counter, and the plan starts from that.
Material built to the approved information
Visual aid, leave behind literature and product cards, each claim traceable. Material goes out approved rather than being corrected in the field.
Prescriber facing detailing
Calls on consultants and hospital units, scientific rather than promotional in tone, and repeated. One call has never built a brand.
Stockist availability behind the demand
A prescription that cannot be dispensed is worse than no prescription. Stock is placed with stockists and distributors in the catchment before the detailing effort reaches volume.
Before you choose this route
In different products, yes, and several partners do exactly that. In the same product it does not work: the same carton cannot be both territory exclusive and freely available through the stockist chain.
Not on territory, and any company promising you both territory monopoly and open stockist supply on one brand is promising two things that contradict each other. What you get here is a brand that keeps its own identity as it grows.
Material for the ethical range is produced here, because the claims on it are the manufacturer’s responsibility under the code. That is a compliance position rather than a commercial concession.
A stockist stocks what is already asked for. An ethical division creates the asking. The supply chain is the easy half.
Talk through which route fits
Tell us the molecules you are interested in and how you already reach clinicians. We will say plainly which of the two arrangements suits, including when it is the other one.